Brief Review on Repurposed Drugs and Vaccines for Possible Treatment of COVID-19

Overview

Journal Eur J Pharmacol

Specialty Pharmacology

Date 2021 Feb 27

PMID 33639193

Citations 19

Authors

Priyasha De

Ishita Chakraborty

Bhargavi Karna

Nirmal Mazumder

Affiliations

Soon will be listed here.

Abstract

Severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2), the causative agent of the pandemic coronavirus disease 2019 (Covid-19) has claimed more than a million lives. Various in silico, in vitro, and in vivo studies are being conducted to understand the effect of SARS-CoV-2 on the cellular metabolism of humans and the various drugs and drug-targets that may be used. In this review, we discuss protein-protein interactions (PPIs) between viral and human proteins as well as viral targets like proteases. We try to understand the molecular mechanism of various repurposed antiviral drugs against SARS-CoV-2, their combination therapies, drug dosage regimens, and their adverse effects along with possible alternatives like non-toxic antiviral phytochemicals. Ultimately, randomized controlled trials are needed to identify which of these compounds has the required balance of efficacy and safety. We also focus on the recent advancements in diagnostic methods and vaccine candidates developed around the world to fight against Covid-19.

Citing Articles

Integrating Quantum Mechanics into Protein-Ligand Docking: Toward Higher Accuracy and Reliability.

Fusti-Molnar L Res Sq. 2024; .

PMID: 39678339 PMC: 11643324. DOI: 10.21203/rs.3.rs-5433993/v1.

Exploring the key structural attributes and chemico-biological interactions of pyridinone-based SARS-CoV-2 3CL inhibitors through validated structure-based drug design strategies.

Banerjee S, Baidya S, Ghosh B, Jha T, Adhikari N Heliyon. 2024; 10(23):e40404.

PMID: 39654708 PMC: 11626027. DOI: 10.1016/j.heliyon.2024.e40404.

Docking Studies and Molecular Dynamics Simulations of Potential Inhibitors from the Brown Seaweed (Phaeophyceae) against PLpro of SARS-CoV-2.

Tassakka A, Iskandar I, Alam J, Permana A, Massi M, Sulfahri BioTech (Basel). 2023; 12(2).

PMID: 37366794 PMC: 10296136. DOI: 10.3390/biotech12020046.

Supervised Machine Learning Models to Identify Early-Stage Symptoms of SARS-CoV-2.

Dritsas E, Trigka M Sensors (Basel). 2023; 23(1).

PMID: 36616638 PMC: 9824026. DOI: 10.3390/s23010040.

Iran's Struggling Health System in the Policy of Managing the COVID-19 Pandemic.

Pourasghari H, Rezapour A, Tahernezhad A, Mazaheri E, Nikoo R, Jabbari A Int J Prev Med. 2022; 13:131.

PMID: 36452466 PMC: 9704485. DOI: 10.4103/ijpvm.ijpvm_291_21.

References

Pierre F, Chua P, OBrien S, Siddiqui-Jain A, Bourbon P, Haddach M . Discovery and SAR of 5-(3-chlorophenylamino)benzo[c][2,6]naphthyridine-8-carboxylic acid (CX-4945), the first clinical stage inhibitor of protein kinase CK2 for the treatment of cancer. J Med Chem. 2010; 54(2):635-54. DOI: 10.1021/jm101251q. View

Kramer O, Zhu P, Ostendorff H, Golebiewski M, Tiefenbach J, Peters M . The histone deacetylase inhibitor valproic acid selectively induces proteasomal degradation of HDAC2. EMBO J. 2003; 22(13):3411-20. PMC: 165640. DOI: 10.1093/emboj/cdg315. View

Muller C, Schulte F, Lange-Grunweller K, Obermann W, Madhugiri R, Pleschka S . Broad-spectrum antiviral activity of the eIF4A inhibitor silvestrol against corona- and picornaviruses. Antiviral Res. 2017; 150:123-129. PMC: 7113723. DOI: 10.1016/j.antiviral.2017.12.010. View

Ul Haq F, Roman M, Ahmad K, Rahman S, Shah S, Suleman N . Artemisia annua: Trials are needed for COVID-19. Phytother Res. 2020; 34(10):2423-2424. PMC: 7276816. DOI: 10.1002/ptr.6733. View

Loutfy M, Blatt L, Siminovitch K, Ward S, Wolff B, Lho H . Interferon alfacon-1 plus corticosteroids in severe acute respiratory syndrome: a preliminary study. JAMA. 2003; 290(24):3222-8. DOI: 10.1001/jama.290.24.3222. View

Mitsuda T, Omi T, Tanimukai H, Sakagami Y, Tagami S, Okochi M . Sigma-1Rs are upregulated via PERK/eIF2α/ATF4 pathway and execute protective function in ER stress. Biochem Biophys Res Commun. 2011; 415(3):519-25. DOI: 10.1016/j.bbrc.2011.10.113. View

Yang Z, Huang Y, Ganesh L, Leung K, Kong W, Schwartz O . pH-dependent entry of severe acute respiratory syndrome coronavirus is mediated by the spike glycoprotein and enhanced by dendritic cell transfer through DC-SIGN. J Virol. 2004; 78(11):5642-50. PMC: 415834. DOI: 10.1128/JVI.78.11.5642-5650.2004. View

Faria P, Chakraborty P, Levay A, Barber G, Ezelle H, Enninga J . VSV disrupts the Rae1/mrnp41 mRNA nuclear export pathway. Mol Cell. 2005; 17(1):93-102. DOI: 10.1016/j.molcel.2004.11.023. View

Adedeji A, Severson W, Jonsson C, Singh K, Weiss S, Sarafianos S . Novel inhibitors of severe acute respiratory syndrome coronavirus entry that act by three distinct mechanisms. J Virol. 2013; 87(14):8017-28. PMC: 3700180. DOI: 10.1128/JVI.00998-13. View

10.

Gao J, Hu S . Update on use of chloroquine/hydroxychloroquine to treat coronavirus disease 2019 (COVID-19). Biosci Trends. 2020; 14(2):156-158. DOI: 10.5582/bst.2020.03072. View

11.

Cao B, Wang Y, Wen D, Liu W, Wang J, Fan G . A Trial of Lopinavir-Ritonavir in Adults Hospitalized with Severe Covid-19. N Engl J Med. 2020; 382(19):1787-1799. PMC: 7121492. DOI: 10.1056/NEJMoa2001282. View

12.

Zhou D, Dai S, Tong Q . COVID-19: a recommendation to examine the effect of hydroxychloroquine in preventing infection and progression. J Antimicrob Chemother. 2020; 75(7):1667-1670. PMC: 7184499. DOI: 10.1093/jac/dkaa114. View

13.

de Abajo F, Hernandez R, Kaminer I, Meyerhans A, Rosell-Llompart J, Sanchez-Elsner T . Back to Normal: An Old Physics Route to Reduce SARS-CoV-2 Transmission in Indoor Spaces. ACS Nano. 2020; 14(7):7704-7713. DOI: 10.1021/acsnano.0c04596. View

14.

Mingo R, Simmons J, Shoemaker C, Nelson E, Schornberg K, DSouza R . Ebola virus and severe acute respiratory syndrome coronavirus display late cell entry kinetics: evidence that transport to NPC1+ endolysosomes is a rate-defining step. J Virol. 2015; 89(5):2931-43. PMC: 4325712. DOI: 10.1128/JVI.03398-14. View

15.

Kumar K, Lupoli T . Exploiting Existing Molecular Scaffolds for Long-Term COVID Treatment. ACS Med Chem Lett. 2020; 11(7):1357-1360. PMC: 7269097. DOI: 10.1021/acsmedchemlett.0c00254. View

16.

Folegatti P, Ewer K, Aley P, Angus B, Becker S, Belij-Rammerstorfer S . Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial. Lancet. 2020; 396(10249):467-478. PMC: 7445431. DOI: 10.1016/S0140-6736(20)31604-4. View

17.

Roden D, Harrington R, Poppas A, Russo A . Considerations for Drug Interactions on QTc in Exploratory COVID-19 Treatment. Circulation. 2020; 141(24):e906-e907. DOI: 10.1161/CIRCULATIONAHA.120.047521. View

18.

Xu P, Ye S, Li K, Huang M, Wang Q, Zeng S . NOS1 inhibits the interferon response of cancer cells by S-nitrosylation of HDAC2. J Exp Clin Cancer Res. 2019; 38(1):483. PMC: 6896289. DOI: 10.1186/s13046-019-1448-9. View

19.

Kazama I, Maruyama Y, Murata Y, Sano M . Voltage-dependent biphasic effects of chloroquine on delayed rectifier K(+)-channel currents in murine thymocytes. J Physiol Sci. 2012; 62(3):267-74. PMC: 10716932. DOI: 10.1007/s12576-012-0195-x. View

20.

Zhu N, Zhang D, Wang W, Li X, Yang B, Song J . A Novel Coronavirus from Patients with Pneumonia in China, 2019. N Engl J Med. 2020; 382(8):727-733. PMC: 7092803. DOI: 10.1056/NEJMoa2001017. View